Circulating tumor cells
Download
Report
Transcript Circulating tumor cells
Circulating tumor cells (CTCs) in
blood of breast cancer patients:
Cytological detection and
technical characterization
Enrica Bresaola, Mara Jo Miller, Marco Picozzi, Maria
Teresa Sandri, Chiara Casadio
______________________
Cytology Unit, Department of Pathology & Laboratory Medicine
European Institute of Oncology, Milan, Italy
Introduction
Circulating tumor cells (CTCs) were described for the
first time more than one century ago and their
occurrence in the bloodstream fit with the
hematogenous theory of metastatization
Currently, their detection may play a pivotal role in
the prognosis and prediction of therapy efficacy,
providing us with insights into the clinical outcome,
cell dissemination, drug resistance and treatmentinduced cell death
Purpose
To assess the feasibility of detecting CTCs in blood
samples of breast cancer patients using the Thin Prep®
cytological preparation after a concurrent analysis with
the CellSearch System (Veridex LLC, Warren, NJ)
To further characterize these cells according to estrogen
receptor immunoreactivity and Her-2/neu gene status
evaluation by fluorescence in situ hybridization (FISH)
analysis
Materials and Methods
7.5 ml of whole blood were drawn from breast cancer
patients into the CellSave Preservative Tube containing
a cellular preservative and processed within 72 hours
The CellSearch Profile kit was then utilized to separate
the CTCs by treatment with iron particles coated with
antibodies against the Epithelial Cell Adhesion Molecule
(EpCAM) for capturing CTCs
CTCs were then magnetically separated out and
concentrated into a remaining aliquot of 1ml
Materials and Methods
This aliquot was centrifuged at 1700 rpm for 7 minutes
and the supernatant discarded
The pellet was then added directly into the Preservcyt®
vial for subsequent processing of ThinPrep slides
The slides were colored with H&E and evaluated
microscopically
Estrogen receptor immunostaining and FISH analysis
were carried out according to previously refined
laboratory methods
Results
A total of 106 blood samples, where the CellSearch
System obtained CTCs, were further evaluated
cytologically
Of these, 60 were negative and 46 were positive for
malignant cells (range: 1-615) (Figure 1)
Figure 1
Results
Immunocytochemistry for estrogen receptor was
performed in 7 samples and only one case showed ERpositive tumor cells
+ve cell
-ve cell
10 cases were analyzed by FISH: 7 cases had no
amplification while in 3 cases no more cells were
detected
Conclusions
Cytological detection of CTCs in blood
specimens from breast cancer patients can
be useful in providing samples for testing
predictive indicators of prognosis and clinical
response during therapy